TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05474898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate Iontophoresis +conventional therapy
Description: will receive Mgso4 Iontophoresis in addition to conventional therapy twice a week/4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High- Power Pain Threshold Ultrasound +conventional therapy
Description: will receive HPPT-US on the upper trapezius in addition to conventional therapy twice a week/4 weeks
Study: NCT06730269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Program
Description: The Telerehabilitation Program is a structured rehabilitation regimen designed to improve posture, reduce pain, and strengthen back extensor muscles in children with thoracic hyperkyphosis. Participants in this group followed the Thoracic Corrective Exercise Program, which included four specific exercises targeting thoracic spine correction, performed three times per week over six weeks. The program was delivered remotely through the Fiziu platform, allowing therapists to provide virtual guidance, feedback, and monitoring during the sessions. This approach offered flexibility for families and ensured accessibility to rehabilitation services from the comfort of their homes.
Study: NCT06730230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support
Description: CHWs will implement RPM by being provided with training modules and implementing electronic health record (EHR) support tools for HTN management.
Study: NCT05249621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MZE001
Description: Small molecule inhibitor of muscle glycogen synthase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product containing excipients with no active ingredients
Study: NCT05474898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional theapy
Description: will receive postural correction exercise-stretching and strengthening twice a week/4weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional theapy
Description: will receive postural correction exercise-stretching and strengthening twice a week/4weeks
Study: NCT05741814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Gynecologist guided individualised propofol only sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Gynecologist guided individualised propofol only sedation
Study: NCT06118333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Administration by intravenous infusion
Study: NCT05279768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secretomes
Description: Treatment with tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs and Secretomes
Description: Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Treatment with Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
Study: NCT05474898

Intervention type: OTHER
Group type: OTHER
Intervention: conventional theapy
Description: will receive postural correction exercise-stretching and strengthening twice a week/4weeks
Study: NCT05112159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo tablets to IPG1094 50mg and 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo tablets to IPG1094 50mg and 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo tablets to IPG1094 50mg and 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo tablets to IPG1094 50mg and 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo tablets to IPG1094 50mg and 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo tablets to IPG1094 50mg and 100mg
Study: NCT04889599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH009 (Docetaxel injection)
Description: 75mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel injection
Description: 75mg/m2
Study: NCT04725123

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiome analysis
Description: Stool microbiome analysis of 16S rRNA sequencing to an anticipated number of 8,000,000 reads
Study: NCT05383833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening.
Study: NCT04691167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive trans magnetic stimulation
Description: Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive trans magnetic stimulation
Description: Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.
Study: NCT05946122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: oral atorvastatin for renal protection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo drug
Description: tablet resembles atorvastatin
Study: NCT04226898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synbiotic Supplement
Description: Synbiotic supplement 1 powder stick by mouth daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inert Compound
Description: Synbiotic supplement identical placebo 1 powder stick by mouth daily
Study: NCT06545578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: The Low-level laser (LLL) pain-relief instrument RG-300IB (code E22), manufactured in China, was utilized for low-level laser therapy (LLLT) in Group A . The therapy employed a wavelength of 830 nm (near infrared) and involved careful skin contact hygiene at specified positions, 2.5 and 3.5 cm laterally from the spinous process (L4, L5, or S1) and one distal level segment. The laser operated at a repetition rate of 5,000, with a power density of 300 mW/cm2 and a power output of 10 mW. Each point received 3 J of energy, resulting in a density of 3 J/cm2, with four points. The spot size was 1 cm, and each point received a 30-second treatment. The energy was administered three times per week for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS Intelect Advanced device (Chattanooga, Mouguerre, France). The parameters for TENS stimulation included a frequency range of 60-80 Hz, a pulse width of 50-80 ms, and an intensity of 10-30 mA. Before commencing therapy, patients were provided information regarding the therapeutic approach and any potential adverse effects. During the procedure, two channels (four electrodes) were employed, with one set placed on the right and one on the left paraspinal muscles at the level of L2-L4. Active electrodes from the other channels were affixed 1.5 cm laterally to the spine, while passive electrodes were positioned 3 cm away. TENS therapy was utilized for 30 minutes in Group B, and the intensity of the pain and discomfort was adjusted to the patient's tolerance level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control exercises
Description: Training in coordinated trunk muscle action, including decreasing overactive superficial muscles and independent activation of deep muscles (such as transversus abdominis and multifidus). Exercises for the pelvic floor muscles, controlling respiration, and regulating the position and movement of the spine were added to these exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control exercises
Description: Training in coordinated trunk muscle action, including decreasing overactive superficial muscles and independent activation of deep muscles (such as transversus abdominis and multifidus). Exercises for the pelvic floor muscles, controlling respiration, and regulating the position and movement of the spine were added to these exercises.
Study: NCT05482490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintenance protocol for the hygiene of implant supported prosthesis
Description: Sequence of phases that include the hygiene and cleaning of the prosthesis and the implants, the motivation of the patients and reinforcement of oral hygiene.
Study: NCT05046093

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy
Description: When the lung nodule is visualized by thin bronchoscope (4mm) with R-EBUS, cryobiopsy is performed. If not visualized, ultrathin (3mm) bronchoscope is used.~Cryobiopsy is performed with 1.1mm cryo-probe.
Study: NCT05364034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urban Afforestation Intervention Program
Description: An afforestation intervention program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
Study: NCT05167916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient check cytoscopy
Description: Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine cytology
Description: Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both.
Study: NCT05360914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital at Home (HaH) treatment
Description: The intervention is a new pathway of providing acut treatment for elderly acute ill patients in their own home. If the patient is randomized to the intervention group, the municipalities acute teams start the treatment. The acute team can take venous blood tests, ECG and bladder scan at home. The acute team handles the treatment at home and follows the patient closely. During the treatment course, the acute team and the ED specialist discuss the treatment process either over the phone or virtually on an iPad, where the patient is also involved. If the specialist would like to see the patient for assessment or send the patient for an X-ray, the specialist informs the acute team that the patient must go to a short check-up in the ED. Here, the specialist examines the patient himself and assesses whether the patient can continue to be treated at home, or whether the patient must be admitted to the hospital due to deterioration of the condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard hospital admission
Description: The active comparator is the standard hospital admission for elderly acute ill patients.
Study: NCT04419766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester) house spraying
Description: The spraying will be performed monthly during the first 3 months, bimonthly during the next 6 months and then quarterly thereafter. The spraying will be carried out inside and outside the houses during the morning.
Study: NCT05730348

Intervention type: BEHAVIORAL
Intervention: Post mealtime activity
Description: Therapist lead movement post meals
Study: NCT06463379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: 2 days pulse steroid injection 125 mg methylrednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solumedrol
Description: 2 days pulse steroid injection 125 mg methylrednisolone
Study: NCT06250179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free gingiva graft surgery
Description: For insufficient gingival height in patients, the free gingival graft taken from the palate will be sutured to the relevant area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free gingiva graft surgery
Description: For insufficient gingival height in patients, the free gingival graft taken from the palate will be sutured to the relevant area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free gingiva graft surgery
Description: For insufficient gingival height in patients, the free gingival graft taken from the palate will be sutured to the relevant area.
Study: NCT04277767

Intervention type: DIAGNOSTIC_TEST
Intervention: observational
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: observational
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: observational
Description: No intervention
Study: NCT05209646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bee honey
Description: patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation.
Study: NCT04872907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adhesive system
Description: adhesive system G-BOND. It will be applied to healthy temporary anterior and posterior teeth The adhesive system (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish
Description: The reference drug is a fluoride varnish at 22,600 ppm of the brand Duraphat 50 mg / ml, dental suspension. The varnish is applied to healthy temporary anterior and posterior teeth, on the three sides of the teeth. The reference treatment (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flowable composite
Description: Composite Essentia HiFlo. It will be applied on healthy temporary molar grooves (on side defined by randomization).~Complete or partial renewal of the fluid composite in the grooves of the molars in the event of total or partial loss at 6, 12, 18 months
Study: NCT06357026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Ventricular Assist System（Phigine Medical）
Description: Percutaneous Ventricular Assist System or IABP provides intraoperative circulatory support during high-risk PCI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intra-aortic balloon pump (IABP)
Description: IABP provides intraoperative circulatory support during high-risk PCI.
Study: NCT06266377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of menus of collective catering adapted to the sensory and nutritional needs of subjects with Autism Spectrum Disorder
Description: The AUT-MENU intervention study will be structured in two phases: a preliminary observation phase (T0), which will assess and describe the acceptance of standard meals in the context of collective catering in primary and high schools by the subjects enrolled in the study; and an intervention phase (T1) in which the acceptance of menus targeted to the nutritional and sensory needs of the same subjects enrolled at T0 will be assessed.~The revision of the standard menus will be carried 1) balancing energy and macronutrient content, 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population will be evaluated through meal evaluation forms. These results will be compared with the ones collected during the first observational phase (T0).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education course aimed at caregivers of individuals with Autism Spectrum Disorder
Description: A population subgroup will also be selected whose caregivers will be invited to participate in a nutrition education course with the aim of providing parents of subjects with ASD, with knowledge tools to learn how to identify, manage and reduce their children's attitudes of food selectivity.
Study: NCT04582396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate ganglion block injection
Description: A stellate ganglion block (SGB) is an injection of local anesthetic (numbing medicine) to block the nerves located on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: An injection of normal saline will be injected into muscle on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: The session will be 30 minutes in duration, to be administered by a health professional with experience working with CA patients, the goal will be to establish rapport and help patient identify anxious situations, thoughts, and bodily feelings related their recent CA that could lead to avoidant behavior.~Explain how many of these feelings are common in CA survivors, and they are often unrelated to their risk of its recurrence. Explain how the body has a fight-or-flight system that is controlled in part by the stellate ganglion and explain how blocking the action of this part of the body can reduce the feelings of anxiety that commonly occur. Discuss how certain activities such as exercise can increase feelings of anxiety around bodily sensations, but continued engagement could reduce that fear and that exercise is helpful for recovering from CA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The session will be 30 minutes in duration, to be administered by a health professional with experience working with CA patients, the goal will be to establish rapport and help patient identify anxious situations, thoughts, and bodily feelings related their recent CA that could lead to avoidant behavior.~Explain how many of these feelings are common in CA survivors, and they are often unrelated to their risk of its recurrence. Explain how the body has a fight-or-flight system that is controlled in part by the stellate ganglion and explain how blocking the action of this part of the body can reduce the feelings of anxiety that commonly occur. Discuss how certain activities such as exercise can increase feelings of anxiety around bodily sensations, but continued engagement could reduce that fear and that exercise is helpful for recovering from CA
Study: NCT06227065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin.